Assessment of Prasugrel Antiplatelet P2Y12 Receptor Therapy in a Clopidogrel Nonresponder

被引：0
|
作者：
Ha, Thanh [1 ]
Nathan, Sandeep [2 ]
Mikrut, Krzysztof [1 ]
Miller, Jonathan L. [1 ]
机构：
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2010年 / 134卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
77
引用
收藏
页码：509 / 510
页数：2
相关论文
共 50 条
  • [1] Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
    Mousa, Shaker A.
    Jeske, Walter P.
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (02) : 170 - 176
  • [2] Addressing clopidogrel's variable antiplatelet effect with Prasugrel, a novel P2Y12 antagonist
    Jakubowski, Joseph
    PURINERGIC SIGNALLING, 2008, 4 : S74 - S74
  • [3] Cangrelor inhibits the binding of clopidogrel and prasugrel active metabolites to the P2Y12 receptor
    Buckland, R.
    Judge, H. M.
    Sugidachi, A.
    Jakubowski, J. A.
    Storey, R. F.
    EUROPEAN HEART JOURNAL, 2009, 30 : 193 - 193
  • [4] Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Varenhorst, Christoph
    James, Stefan
    Erlinge, David
    Braun, Oscar O.
    Brandt, John T.
    Winters, Kenneth J.
    Jakubowski, Joseph A.
    Olofsson, Sylvia
    Wallentin, Lars
    Slegbahn, Agneta
    AMERICAN HEART JOURNAL, 2009, 157 (03) : 562.e1 - 562.e9
  • [5] Antiplatelet Therapy n ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
    Ristorto, Jessica
    Messas, Nathan
    Marchandot, Benjamin
    Kibler, Marion
    Hess, Sebastien
    Meyer, Nicolas
    Schaeffer, Michael
    Tuzin, Nicolas
    Ohlmann, Patrick
    Jesel, Laurence
    Morel, Olivier
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (08) : 674 - 689
  • [6] Reversible binding of cangrelor to the P2Y12 receptor prevents the binding of clopidogrel and prasugrel active metabolites
    Buckland, R. J.
    Judge, H. M.
    Sugidachi, A.
    Jakubowski, J. A.
    Storey, R. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 942 - 942
  • [7] New Perspectives for Antiplatelet Therapy: The Evolution of P2Y12 Receptor Antagonists
    da Silva, Paula Nogueira
    Barbosa, Maria Leticia de Castro
    REVISTA VIRTUAL DE QUIMICA, 2021, 13 (04) : 999 - 1016
  • [8] Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls
    Winter, Max-Paul
    Kozinski, Marek
    Kubica, Jacek
    Aradi, Daniel
    Siller-Matula, Jolanta M.
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2015, 11 (04): : 259 - 280
  • [9] P2Y12 receptor constitutive activity as a new target for antiplatelet therapy
    Garcia, C.
    Ribes, A.
    Nauze, M.
    N'guyen, D.
    Martinez, L. O.
    Payrastre, B.
    Senard, J. M.
    Gales, C.
    Pons, V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 29 - 29
  • [10] The antiplatelet effect of ASP1645, a novel P2Y12 receptor antagonist, compared with clopidogrel
    Uemura, T.
    Kawasaki, T.
    Sakata, C.
    Shigenaga, T.
    Moritani, Y.
    Takasaki, J.
    Koga, Y.
    Ito, H.
    Mutoh, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 946 - 946
12345